Biointron的动态

Featured highlights from today's Efortless Update: [Clinical Trials] 07/15 「Everest Medicines reports phase 3 trial of VELSIPITY achieves significant improvements in ulcerative colitis at week 40 in Asia」 07/15 「Camurus reports ACROINNOVA 2 phase 3 study results of octreotide SC depot in acromegaly showing safety and improved treatment response over 52 weeks」 07/15 「Lexeo Therapeutics reports interim clinical trial data of LX2006 with 11.4% reduction in LVMI at 12 months for Friedreich ataxia cardiomyopathy」 same day : ( ↓ NASDAQ: LXEO | -23.27% ) [Deals] 07/15 「GC Cell and Checkpoint Therapeutics Inc to explore synergistic cancer treatments with cosibelimab and Immuncell-LC」 same day : ( ↑ NASDAQ: CKPT | +1.7% ) 07/15 「Lantheus bolsters Alzheimer's diagnostics with acquisition of Meilleur Technologies and phase 3 NAV-4694 agent, backed by advisors Chestnut Partners and legal teams Goodwin Procter, Foley Hoag」 same day : ( ↑ NASDAQ: LNTH | +0.41% ) 07/14 「Nona Biosciences collaborates with Alaya.bio to develop CAR-T cell therapies using HCAb Harbour Mice platform and polymeric delivery technology」 [Regulatory] 07/15 「FDA grants Fast Track Designation to Oricell Therapeutics' OriCAR-017 for relapsed/refractory multiple myeloma as Phase I trials proceed」 07/12 「Mabwell (Shanghai) Bioscience Co., Ltd.'s ADC 9MW2821 receives Fast Track Designation from FDA for Nectin-4 positive triple negative breast cancer」 View the full newsletter contents for free via the link in the comments.

Regeneron Pharmaceuticals revealed promising findings from the Phase I/II LINKER-MM1 trial of linvoseltamab in patients suffering with relapsed/refractory multiple myeloma during the oral plenary session at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. Linvoseltamab, an investigational bispecific antibody, demonstrates its potential by bridging B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells, thereby triggering T-cell activation and subsequent cancer-cell elimination. For more detailed analysis, read: https://lnkd.in/g3biP3MT #multiplemyeloma #linvoseltamab #relapsedrefractorymultiplemyeloma #clincialtrials #cancer #cancercells #oncology #regeneron #healthcare?#biotechnology?#lifesciences?#pharmaceuticalindustry?#pharmaceutical?#marketresearch?#marketforecast?#markettrends?#consulting?#healthcareconsulting?#consultingservices?#marketforecast

?????? ???????????????? ??????????’?? ?????????????????? ?????? ??????????????????-?????????? ?????????? ???????? ???????????? The FDA approved Amgen’s Amgen bispecific T-cell engager tarlatamab, now branded as Imdelltra, for treating extensive-stage small lung cancer (ES-SCLC) in patients who have progressed after platinum chemotherapy. Approved under the accelerated pathway based on treatment response and duration data, Imdelltra requires a Phase III confirmatory trial to maintain approval. It carries a boxed warning for cytokine release syndrome and neurologic toxicity. Jay Bradner Jay Bradner, CSO at Amgen, highlighted this as a pivotal moment for ES-SCLC patients, describing Imdelltra as a transformative option with long-lasting responses, especially in those previously treated. Administered as an intravenous infusion, Imdelltra is a first-in-class bispecific antibody targeting DLL3 on tumor cells and CD3 on T cells, activating the immune system to destroy DLL3-expressing cancer cells. DLL3 is expressed in 85% to 96% of SCLC cases but rarely found on healthy cells. Amgen is also developing tarlatamab for neuroendocrine prostate cancer, currently in Phase I. The approval was based on the Phase II DeLLphi-301 trial, where Imdelltra showed an objective response rate of 40% and 32% at 10-mg and 100-mg doses, respectively. Of those with objective response, 59% sustained the response for a median of at least six months. Median progression-free survival was 4.9 months in the 10-mg group, with overall survival at 14.3 months. With these results, Amgen filed its Biologics License Application, accepted by the FDA in December 2023 with priority review. Approval was initially due on June 12, 2024. Imdelltra’s approval positions Amgen ahead of competitors like Boehringer Ingelheim and Novartis/Legend Biotech, who are developing similar therapies. #FDAApproval #Biotech #CancerTreatment #LungCancer #Immunotherapy #Amgen #HealthcareInnovation #MedicalResearch

? Stay at the forefront of Oncology advancements! Our Daily Digest every Tuesday delivers essential insights and trends shaping the future of cancer treatments. ? ?? Obsidian Therapeutics partners with Bristol Myers Squibb and Vertex Pharmaceuticals to advance innovative therapies powered by its proprietary cytoDRiVE? technology. ?? SillaJen and BeiGene initiated a clinical trial combining Sillajen’s BAL0891 with BeiGene’s PD-1 inhibitor, tislelizumab, to advance innovative solid tumor therapies. ?? Bayer Submits Darolutamide for Approval in China, Backed by Phase III ARANOTE Trial Showing Reduced Disease Progression Risk. ?? GSK'227 Earns FDA Breakthrough Designation for Relapsed/Refractory Osteosarcoma, spotlighting its potential to transform treatment options. ?? FDA Approves OPDIVO Qvantig? (nivolumab + hyaluronidase-nvhy) US HCP Injection, Expanding PD-1 Inhibitor Treatment Options for Solid Tumors. This first-of-its-kind subcutaneous formulation of Opdivo? (nivolumab) showed consistent efficacy and comparable safety to the intravenous version in Phase 3 CheckMate-67T trial. ?? Brigham Study Shows Glucarpidase Improves Kidney Recovery in Methotrexate-Induced Toxicity for Cancer Patients ?? Astellas Pharma' Vyloy Approved in China for Advanced Gastric Cancer: NMPA clears Vyloy (zolbetuximab) as a first-line treatment for HER2-negative gastric and gastroesophageal junction adenocarcinoma. ?? Innovent Biologics Advances Oncology Development with Eli Lilly and Company and Sanofi Partnerships, highlighting its robust drug pipeline at the J.P. Morgan Conference. ?? Amgen's IMDYLLTRA[CI1]?? (tarlatamab-dlle) Gains UK Conditional Approval for Advanced Lung Cancer, offering new hope for extensive-stage small cell lung cancer (ES-SCLC) patients ----- ?? Don't forget to sign up for daily updates within the pharma and biotech industry. #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #Amgen #EliLilly #Sanofi #vertex #beigene #AstraZeneca #BMS #lilly #astellas #GSK #bayer

?? ???????????????? ????????: ???????????????? ???????????????? ?????? ??????????????????????? - ????????????????-?????? ???????????????? (??.??.??) ?? Today, Eckert & Ziegler SE's proprietary Theralugand? has ???????????????? ???????????????? from the ???????????????? ????????????????????! ?? This milestone marks a new era for our non-carrier added Lutetium-177 chloride, which is now ?????????? ?????? ?????????????? ???????????????? ???????????????????????? across the ???????????????? ???????????????? ???????? (EEA). ?? Theralugand? offers ????????-????????????, ??????-?????????????????? ????????????????-?????? designed for the labeling of radiopharmaceuticals, enabling innovative therapies for conditions like neuroendocrine tumors and metastatic prostate cancer. ???????????????????? ?????????????? ???? ?????????????????????????????? ??????, Theralugand? can now support ?????????????? ???????????????? ????????????????????. ?? Through ???????????????????????? ???????? ???????????????????????????? ???????????????????? worldwide, Eckert & Ziegler is advancing targeted radiotherapies, addressing the ?????????????? ???????????? for reliable therapeutic radioisotopes. ?? ?? Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE, shares: “We are excited to achieve the ???? ???????????????? ?????? ???????????????????????, a critical step in making innovative treatment options ???????????? ?????????????????? ?????? ???????????????? ???????????????????????? ???????????? ????????????. This accomplishment reflects our ???????????????????? ???? ?????? ???????????????????? ?????? ???????????????????????? ???? ???????????????? ?????????????????????? ????????????????????????????????????????.” We’re ?????????????? ???? ???????????????????? to ensure a ???????????? ???????????? ???? ????????????????-??????, contributing to the continued evolution of cancer care globally. ?? Read the full press release - Link in the comments below ?? #NuclearMedicine #RadioligandTherapy #Radiopharmaceuticals #Lutetium #ContributingToSavingLives ?

#WeeklyDigest Upgrading Cancer Treatment and Drug Development ?? Stay ahead in the fight against cancer and the forefront of pharmaceutical innovation with this week’s highlights by The Babak Lab. Learn about groundbreaking research, cutting-edge technologies, and transformative AI applications poised to redefine treatment paradigms. Whether you’re a healthcare professional, a researcher, or someone passionate about medical advancements, these insights will inspire and inform. ?? Revolutionizing Treatment for Deadly Triple-Negative Breast Cancer This research could significantly accelerate the availability of safe and effective treatments for TNBC patients, a group with limited options. ?? Read more: https://lnkd.in/gEUfD3Y6 ?? AI is Transforming Drug Development AI’s ability to streamline drug development promises faster, cheaper, and more personalized treatment options, potentially revolutionizing the pharmaceutical industry. ?? Read more: https://lnkd.in/ga2ATGqw ?? Discover the Cutting-Edge Technologies in Cancer Care The integration of advanced technologies is transforming cancer care, offering hope for more efficient, precise, and effective treatments. ?? Read more: https://lnkd.in/gJ4f_cA9 Stay tuned for more breakthroughs in cancer research and drug development. Let's continue to support and celebrate innovations that bring us closer to effective treatments and improved patient outcomes. #CancerResearch?#BreastCancerAwareness?#AIinHealthcare?#DrugDevelopment?#Biotechnology?#PharmaceuticalInnovation?#MedicalResearch?#GeneEditing?#Nanotechnology?#HealthcareInnovation?#FutureOfMedicine?#CancerTreatment?#ClinicalTrials?#PrecisionMedicine?#HealthTech

September Life Science Highlights: What You Need to Know While the Life Science market may not be moving at record speed, there’s still plenty of exciting progress happening across the biotech and pharmaceutical landscape. September, in particular, saw some key milestones worth celebrating: 1?? Candid Therapeutics launched innovative T-cell engager antibodies aimed at combating autoimmunity. 2?? Telix Pharmaceuticals released impressive Phase III results, making a strong case for advanced kidney cancer imaging. 3?? Novartis gained FDA approval for a treatment that reduces the risk of breast cancer recurrence. 4?? Eli Lilly’s eczema drug finally received FDA approval after an initial setback. 5?? Valneva and Pfizer reported promising Phase II results for their second booster dose of the Lyme disease vaccine. 6?? AI-driven cell therapy is gaining momentum, with Somite AI receiving Orphan Drug and Rare Pediatric Disease designations, accelerating development. These are just a few of the breakthroughs from last month, and there’s more to come. I’d love to hear your thoughts on the latest trends in the Life Science space. Keen to connect with professionals in the space looking to make an impact. #LifeScience #BiotechNews #PharmaceuticalNews #MarketInsights

Almost 15 years after the first therapeutic antibody received FDA approval, another pioneer in antibody therapeutics came up: Gemtuzumab Ozogamicin (Mylotarg), the first antibody-drug conjugate, first approved in 2000 and reapproved in 2017. ?? Antibody type: Humanized IgG4, Antibody-Drug Conjugate (ADC) ?? Brand name: Mylotarg ?? Company: Wyeth Pharmaceuticals, now part of Pfizer, and Celltech ?? First indication: Acute myeloid leukemia (AML) Gemtuzumab Ozogamicin revolutionized cancer treatment with its innovative design, combining a monoclonal antibody targeting CD33 with a potent chemotherapy agent, calicheamicin. This ingenious strategy allows for the precise delivery of the cytotoxic drug to leukemic cells, reducing harm to healthy tissues and enhancing therapeutic efficacy. Although initially withdrawn due to safety concerns, Mylotarg was reapproved in 2017. Today, it stands as a pioneer in targeted cancer therapies, offering new hope to patients battling AML. Stay tuned for our next post as we continue to explore more groundbreaking FDA-approved antibodies! #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #CancerTherapy #AML #Biotechnology #MedicalInnovation

NorthStar Medical Radioisotopes, LLC has entered into a collaboration deal with YAP Therapeutics, Inc., to develop and produce #radiopharmaceuticals aimed at treating cancer and other chronic diseases. Dr. Frank Scholz YAP Therapeutics, Inc. #healthcare #PharmaIndustrialIndia

???????????? ???????????? ???????????????????????? ???????????????? ???????????? ????????-????????. ???????????? ???????????????? ???????????? ???? ???????? ?????? ???????????? ?????????? ?????? ???????????? ???? ???????????? ???????????? ???????????????????????? ???????????????? ????????????. ?????????????? ?????? ???????????? ??????: https://lnkd.in/dm66Xegi #Immunotherapy is a type of medical treatment that harnesses the body's own immune system to fight diseases, particularly cancer. Unlike traditional treatments such as chemotherapy and radiation therapy, which directly target cancer cells, immunotherapy stimulates the body's natural defenses to identify and destroy cancer cells more effectively. It is a type of personalized treatment. (Immunotherapy is often tailored to the patient's specific cancer and immune system. Biomarker testing is sometimes performed to determine the suitability of certain immunotherapy drugs.) This report is a detailed and comprehensive analysis for global #Cancer Immuno Personalized Medicine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. *???? ????????:??Immune Checkpoint Inhibitors,?Cytokine-Based Immunotherapy, CAR-T Cell Therapy *???? ??????????????????????:?Lung Cancer, Breast Cancer,?Prostate Cancer,?Blood-related Cancer *???? ??????????????: North America, Europe, Asia-Pacific, South America, Middle East & Africa *???? ?????? ??????????????: AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol Myers Squibb, Amgen, AstraZeneca, Merck, Takeda, Merck KGaA, Darmstadt, Germany, Seagen, Eli Lilly and Company, ONO PHARMACEUTICAL CO., LTD., Pfizer, GSK, Exelixis, Regeneron, Innovent Biologics, Hengrui Pharma Co.,Ltd #CancerImmunotherapy #PersonalizedMedicine #CancerTreatment #Immunotherapy #Oncology #PrecisionMedicine #CancerResearch #MedicalInnovation #Healthcare #CancerCare #ImmunoOncology #Biotechnology #CancerAwareness #TargetedTherapy #PatientCare #MedicalAdvancements #CancerDiagnosis #ImmunotherapyResearch #CancerSurvivor #HealthTech